THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced ... with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...